BruceDavidChesonMD

Oncology • Bethesda, MD

Hematologic Oncology

Professor, Medicine, Georgetown University School of Medicine

Join to view full profile

Dr. Cheson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cheson's full profile

Already have an account?

Office
6410 Rockledge Dr
Bethesda, MD 20817
Phone+1 301-571-0019

Fax+1 240-482-0555

Education & Training

Tufts University School of MedicineClass of 1971
University of Virginia Medical CenterResidency, Internal Medicine

Certifications & Licensure

MD State Medical License 1987 - 2026
DC State Medical License 1994 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2006-2014
CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Top Doctors:Washington DC Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012
Northern Virginia Magazine Castle Connolly, 2007-2008
Fellow (FASCO) American Society of Clinical Oncologists, 2007
Join now to see all

Clinical Trials

Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Feb 01
Completed
Phase 2
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) Start of enrollment: 2009 Feb 01
Completed
Phase 1
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2010 Apr 01
Terminated
Phase 2
Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma Start of enrollment: 2010 Sep 01
Completed
Phase 2
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
Terminated
Phase 3
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma Start of enrollment: 2016 May 13
Active, not recruiting
Phase 2
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2017 Nov 30
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

1297 citations
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson, Peter L. Greenberg, John M. Bennett, Bob Löwenberg, Pierre W. Wijermans
Blood. 2006-07-15
116 citations
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
Ayalew Tefferi, Hagop M. Kantarjian, S. Vincent Rajkumar, Larry Baker, J L Abkowitz
Mayo Clinic Proceedings. 2015-08-01
162 citations
Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909
Lloyd E. Damon, Jeffrey L. Johnson, Donna Niedzwiecki, Bruce D. Cheson, David D. Hurd
Journal of Clinical Oncology. 2009-12-20

Journal Articles

Combinations or Sequences of Targeted Agents in CLL: Is the Whole Greater Than the Sum of Its Parts (Aristotle, 360 BC)?
Bruce Cheson, MD, Blood
CALBG 50604: Risk-Adapted Treatment of Non-Bulky Early Stage Hodgkin Lymphoma Based on Interim PET
David J Straus, Heiko Schoder, Bruce D Cheson, John C Grecula, Lale Kostakoglu, Eric D Hsi, Leslie L Popplewell, John P Leonard, Craig H Moskowitz, Brad S Kahl, Jonath..., Blood
Real World Outcomes and Management Strategies for Venetoclax-Treated Chronic Lymphocytic Leukemia Patients in the United States
Arun K Singavi, Andrew Zelenetz, Nicole Lamanna, Bruce D Cheson, Richard R Furman, Jakub Svoboda, Stephen J Schuster, John N Allan, Chaitra S Ujjani, Haematologica

Abstracts/Posters

Long-Term Follow-up of Follicular Lymphoma (FL) Patients (pts) Demonstrating Undetectable Minimal Residual Disease (MRD) Using a Next-Generation Based DNA Assay: Suppo...
Bruce D. Cheson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
Bruce D. Cheson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
Bruce D. Cheson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma
Bruce D. Cheson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analys...
Bruce D. Cheson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patie...
Bruce D. Cheson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
Bruce D. Cheson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
Bruce D. Cheson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia (Part 1 of a 2-Part Series)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
External Validation and Revision of Thrombosis Lymphoma /Throly/ Score
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

4 Oncologists on the MoveJune 8th, 2021
Brentuximab Vedotin plus Nivolumab as Chemotherapy-Free Strategy for Hodgkin Lymphoma in Older PatientsOctober 19th, 2020
Thanks. Feedback Improves Google AdsSeptember 17th, 2019
Join now to see all